1. CLL Trialists' Collaborative Group Chemotheraputic Options in Chronic Lymphocytic Leukemia: a Meta-analysis of the Randomized Trials. CLL Trialists' Collaborative Group. J Nat Cancer Instit 1999; 91: 861–8.
2. Dighiero G, Maloum K, Desablens B et al. Chlorambucil in indolent chronic lymphocytic leukemia. N Engl J Med 1998; 338: 1506–14.
3. Stilgenbauer S. Chronic lymphocytic leukemia genetics for predicting outcome. Hematology 2006; 2 (1): 185–90.
4. Rai KR, Peterson BL, Appelbaum FR et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000 Dec 14; 343 (24): 1750–7.
5. Catovsky D, Richards S, Matutes E et al. UK National Cancer Research Institute (NCRI) Haematological Oncology Clinical Studies Group; NCRI Chronic Lymphocytic Leukaemia Working Group. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet 2007; 370 (9583): 230–9.
6. Leporrier M, Chevret S, Cazin B et al. Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood 2001; 98: 2319–25.
7. Balducci L, Yates J. General guidelines for management of older patients with cancer. Oncology 2000; 14: 221–7.
8. Martell RE, Peterson BL, Cohen HJ et al. Analysis of age, estimated creatinine clearance and pretreatment hematologic parameters as predictors of fludarabine toxicity in patients treated for chronic lymphocytic leukemia: a CALGB (9011) coordinated intergroup study. Cancer Chemother Pharmacol. 2002; 50 (1): 37–45.
9. Anaissie EJ, Kontoyiannis DP, O'Brien S et al. Infections in patients with chronic lymphocytic leukemia treated with fludarabine. Ann Intern Med 1998; 129 (7): 559–66.
10. Стадник Е.А., Никитин Е.А., Бидерман Б.В. и др. Ретроспективное сравнение эффективности и токсичности режимов FC и FCR у первичных больных В-клеточным хроническим лимфолейкозом. Онкогематология. 2008.
11. Hallek M, Cheson B, Catovsky D et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the InternationalWorkshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008; 111 (12): 5446–56.
12. Cheson BD, Bennett JM, Grever M et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996; 87: 4990–7.
13. Eichhorst BF, Busch R, Hopfinger G et al. German CLL Study Group. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 20061; 107 (3): 885–91.
14. Tam CS, O'Brien S, Wierda W et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008; 112 (4): 975–80.
15. Elter T, Borchmann P, Schulz H et al. Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial. J Clin Oncol 2005; 23 (28): 7024–31.
16. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16 (1): 31–41.
17. Gault MH, Cockcroft DW. Letter: Creatinine clearance and age. Lancet 1975; 2 (7935): 612–3.
18. Karlsson C, Norin S, Kimby E et al. Alemtuzumab as first-line therapy for B-cell chronic lymphocytic leukemia: long-term follow-up of clinical effects, infectious complications and risk of Richter transformation. Leukemia 2006; 20 (12): 2204–7.
19. Lundin J, Kimby E, Björkholm M et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 2002; 100 (3): 768–73.
20. Moreton P, Kennedy B, Lucas G et al. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol 2005; 23 (13): 2971–9.
21. Osterborg A, Karlsson C, Lundin J et al. Strategies in the management of alemtuzumab-related side effects. Semin Oncol 2006; 33 (2 Suppl. 5): S29–35.
22. Keating M, Coutre S, Rai K et al. Management guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukemia. Clin Lymphoma. 2004; 4 (4): 220–7.
23. Montserrat E, Rozman C. Chronic lymphocytic leukaemia: prognostic factors and natural history. Bailliere's Clin Haematol 1993; 6: 849–66.
24. Garratty G. Immune hemolytic anemia associated with negative routine serology. Semin Hematol 2005; 42 (3): 156–64.
25. Cortes J, O'Brien S, Loscertales J et al. M. Cyclosporin A for the treatment of cytopenia associated with chronic lymphocytic leukemia. Cancer. 2001; 92 (8): 2016–22.
26. Chapel HM, Bunch C. Mechanisms of infection in chronic lymphocytic leukemia. Semin Hematol 1987; 24 (4): 291–6.
27. Oscier D, Fegan C, Hillmen P et al. Guidelines on the diagnosis and management of chronic lymphocytic leukemia. Br J Haematol 2004; 125: 294–317.
28. Morrison VA. Management of infectious complications in patients with chronic lymphocytic leukemia. Hematol Am Soc Hematol Educ Program 2007; 332–8.
29. Weeks JC, Tierney MR, Weinstein MC. Cost effectiveness of prophylactic intravenous immune globulin in chronic lymphocytic leukemia. New Engl J Med 1991; 325: 81–6.
30. Boughton BJ, Jackson N, Lim S, Smith N. Randomized trial of intravenous immunoglobulin prophylaxis for patients with chronic lymphocytic leukaemia and secondary hypogammaglobulinaemia. Clin Lab Haematol 1995; 17: 75–80.
31. Chapel H, Dicato M, Gamm H et al. Immunoglobulin replacement in patients with chronic lymphocytic leukaemia: a comparison of two dose regimens. Br J Haematol 1994; 88: 209–12.
32. Jurlander J, Geisler CH, Hansen MM. Treatment of hypogammaglobulinaemia in chronic lymphocytic leukaemia by low-dose intravenous gammaglobulin. Eur J Haematol 1994; 53 (2): 114–8.